ATP Synthase Inhibition of Mycobacterium avium Is Not Bactericidal
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
The efficacy of ATP synthase inhibitor TMC207 was assessed in early and late Mycobacterium avium infections in mice. In contrast to what was earlier observed for M. tuberculosis , a bacteriostatic effect was obtained. In vitro, the minimal bactericidal concentration (MBC)/MIC ratio was very high. The MBC was more relevant for assessment of pharmacokinetic/pharmacodynamic relationships than the MIC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TMC207 is bactericidal towards most species of mycobacteria (109), but is only bacteriostatic against M. avium (118) and M. smegmatis (Berney and Cook, unpublished data).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [118]
Citations
Cites
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191 · cited 2×
“060 g/ml (1), the weak in vivo activity of TMC207 against M.”
BackgroundResultSelf-citationThe Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis
Diacon, A. H., Pym, A., Grobusch, M., Patientia, R., Rustomjee, R., Page-Shipp, L., Pistorius, C., Krause, R., Bogoshi, M., Churchyard, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808427 · Cited by 835
Self-citationMouton, J. W., Dudley, M. N., Cars, O., Derendorf, H., & Drusano, G. L. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki079 · Cited by 549 · cited 2×
“For drugs with a high MBC/MIC ratio, parameters referring to the MBC (such as the area under the bactericidal curve [AUBC]) (14) are probably more relevant.”
BackgroundMethodPulmonary Mycobacterial Infections due to Mycobacterium intracellulare-avium Complex
Rosenzweig, D. Y. (1979) · Chest · doi:10.1378/chest.75.2.115 · Cited by 200 · cited 1×
“Mycobacterium avium is a pathogen that causes disseminated disease in immunocompromised individuals and pulmonary disease in immunocompetent adults (15) and is far less susceptible than Mycobacterium tuberculosis to most antimicrobial agents; treatment options are very limited (7, 10).”
BackgroundHuang, J. H., Kao, P. N., Adi, V., & Ruoss, S. J. (1999) · Chest · doi:10.1378/chest.115.4.1033 · Cited by 195
In Vitro Antimycobacterial Spectrum of a Diarylquinoline ATP Synthase Inhibitor
Huitric, E., Verhasselt, P., Andries, K., & Hoffner, S. E. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00181-07 · Cited by 172 · cited 1×
“015 g/ml, consistent with earlier estimates (1, 8).”
ResultSelf-citationIn vitro and in vivo activities of clarithromycin against Mycobacterium avium
Fernandes, P. B., Hardy, D. J., McDaniel, D., Hanson, C. W., & Swanson, R. N. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.9.1531 · Cited by 158
Lounis, N., Véziris, N., Chauffour, A., Truffot-Pernot, C., Andries, K., & Jarlier, V. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00766-06 · Cited by 143
Self-citationBenson, C. A., Williams, P. L., Currier, J. S., Holland, F., Mahon, L. F., MacGregor, R. R., Inderlied, C. B., Flexner, C. W., Neidig, J. L., Chaisson, R. E., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/378807 · Cited by 142
Ethambutol Ocular Toxicity in Treatment Regimens for Mycobacterium avium Complex Lung Disease
Griffith, D. E., Brown-Elliott, B. A., Shepherd, S., McLarty, J., Griffith, L., & Wallace, R. J. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200407-863oc · Cited by 125 · cited 1×
“These regimens are expensive and poorly tolerated (2, 6).”
Background
Cited by
NTM drug discovery: status, gaps and the way forward
Wu, M.-L., Aziz, D. B., Dartois, V., & Dick, T. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.04.001 · Cited by 276
“However, despite being an excellent growth inhibitor at low doses, it lacks bactericidal activity against NTM in vitro [44,46].”
BackgroundPhilley, J. V., Wallace, R. J., Benwill, J. L., Taskar, V., Brown-Elliott, B. A., Thakkar, F., Aksamit, T. R., & Griffith, D. E. (2015) · Chest · doi:10.1378/chest.14-2764 · Cited by 225
Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria
Cook, G. M., Hards, K., Vilchèze, C., Hartman, T., & Berney, M. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mgm2-0015-2013 · Cited by 212
“TMC207 is bactericidal toward most species of mycobacteria (109) but is only bacteriostatic against M. avium (118) and M. smegmatis (M. Berney and G. M. Cook, unpublished data).”
BackgroundTmc207: the First Compound of A New class of Potent Anti-Tuberculosis Drugs
Matteelli, A., Carvalho, A. C., Dooley, K. E., & Kritski, A. (2010) · Future Microbiology · doi:10.2217/fmb.10.50 · Cited by 204
Mycobacterium avium Complex Disease
Daley, C. L. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.tnmi7-0045-2017 · Cited by 277
“The drug is an ATP synthase inhibitor with broad antimycobacterial activity, with MICs ranging from 0.007 to 0.25 μ g/ml for MAC (310, 313).”
BackgroundInfluentialEnergetics of Pathogenic Bacteria and Opportunities for Drug Development
Cook, G. M., Greening, C., Hards, K., & Berney, M. (2014) · Advances in microbial physiology/Advances in Microbial Physiology · doi:10.1016/bs.ampbs.2014.08.001 · Cited by 150
A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis
Fox, G. J., & Menzies, D. (2013) · Infectious Diseases and Therapy · doi:10.1007/s40121-013-0009-3 · Cited by 134
“Bactericidal effect against other mycobacteria [51] (M.”
Dupont, C., Viljoen, A. J., Thomas, S. S., Roquet, F., Herrmann, J., Pethe, K., & Kremer, L. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01225-17 · Cited by 131
Lu, P., Heineke, M. H., Koul, A., Andries, K., Cook, G. M., Lill, H., van Spanning, R., & Bald, D. (2015) · Scientific Reports · doi:10.1038/srep10333 · Cited by 119
Self-citationIn Vivo Evaluation of Antibiotic Activity Against Mycobacterium abscessus
Lerat, I., Cambau, E., Bettoni, R. R. D., Gaillard, J., Jarlier, V., Truffot-Pernot, C., & Véziris, N. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit614 · Cited by 121
“avium [46].”
Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease
Dartois, V. A., & Dick, T. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00897-5 · Cited by 137
“110) but the drug is not bactericidal against MAC and is only bacteriostatic in two mouse models of MAC infection 111 .”
Ruth, M. M., Sangen, J., Remmers, K., Pennings, L. J., Svensson, E. M., Aarnoutse, R. E., Zweijpfenning, S. M. H., Hoefsloot, W., Kuipers, S., Magis-Escurra, C., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky526 · Cited by 110
The Treatment of Rapidly Growing Mycobacterial Infections
Kasperbauer, S. H., & Groote, M. A. D. (2014) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2014.10.004 · Cited by 107
“Although BDQ has excellent bacteriostatic in vitro activity againstM avium andM abscessus, it lacks bactericidal activity in vitro and in vivo.(56,57) Drugs with only bacteriostatic activity are not necessarily without utility.”
BackgroundBedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?
Field, S. K. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315582325 · Cited by 111
“Bedaquiline was almost inactive against a murine model of Mycobacterium abscessus infection but was active against Mycobacterium leprae [Ji et al. 2006a; Lounis et al. 2009; Gelber et al. 2009].”
BackgroundIn Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex
Brown‐Elliott, B. A., Philley, J. V., Griffith, D. E., Thakkar, F., & Wallace, R. J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01798-16 · Cited by 97
“, rifampin or ethambutol) are bactericidal (15).”
BackgroundBedaquiline – The first ATP synthase inhibitor against multi drug resistant tuberculosis
Lakshmanan, M., & Xavier, A. S. (2013) · Journal of Young Pharmacists · doi:10.1016/j.jyp.2013.12.002 · Cited by 103
van Ingen, J., Ferro, B. E., Hoefsloot, W., Boeree, M. J., & van Soolingen, D. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2013.830413 · Cited by 94
Alexander, D. C., Vasireddy, R., Vasireddy, S., Philley, J. V., Brown‐Elliott, B. A., Perry, B. J., Griffith, D. E., Benwill, J. L., Cameron, A. D. S., & Wallace, R. J. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.02087-16 · Cited by 93
“clarithromycin, bactericidal activity is observed after 3 to 4 months of treatment (14).”
BackgroundRifat, D., Chen, L., Kreiswirth, B. N., & Nuermberger, E. L. (2021) · mBio · doi:10.1128/mbio.01049-21 · Cited by 76
New Drugs for the Treatment of Tuberculosis
Ignatius, E. H., & Dooley, K. E. (2019) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.08.001 · Cited by 78
Bioenergetics of Mycobacterium: An Emerging Landscape for Drug Discovery
Iqbal, I., Bajeli, S., Akela, A. K., & Kumar, A. (2018) · Pathogens · doi:10.3390/pathogens7010024 · Cited by 69
In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium abscessus Complex
Brown‐Elliott, B. A., & Wallace, R. J. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01919-18 · Cited by 59
In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria
Aguilar-Ayala, D. A., Cnockaert, M. C., André, E., Andries, K., González-y-Merchand, J. A., Vandamme, P. A. R., Palomino, J. C., & Martin, A. (2017) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000537 · Cited by 62
Self-citationChallenges facing the drug discovery pipeline for non-tuberculous mycobacteria
Soni, I., Groote, M. A. D., Dasgupta, A., & Chopra, S. (2015) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000198 · Cited by 57
Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections
Alffenaar, J. C., Märtson, A., Heysell, S. K., Cho, J., Patanwala, A. E., Burch, G., Kim, H. Y., Sturkenboom, M. G. G., Byrne, A., Marriott, D., et al. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01000-6 · Cited by 54
Looking beyond Typical Treatments for Atypical Mycobacteria
Bento, C. M., Gomes, M. S., & Silva, T. (2020) · Antibiotics · doi:10.3390/antibiotics9010018 · Cited by 53
In vitro activity of bedaquiline against slow-growing nontuberculous mycobacteria
Martin, A., Godino, I. T., Aguilar-Ayala, D. A., Mathys, V., Lounis, N., & Rodriguez‐Villalobos, H. (2019) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001025 · Cited by 32
Self-citationThe looming tide of nontuberculous mycobacterial infections in Portugal and Brazil
Nunes‐Costa, D., Alarico, S., Dalcolmo, M. P., Correia‐Neves, M., & Empadinhas, N. (2015) · Tuberculosis · doi:10.1016/j.tube.2015.09.006 · Cited by 27
New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease
Lee, S. F. K., Laughon, B. E., McHugh, T. D., & Lipman, M. C. I. (2019) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000570 · Cited by 28
Omar, S., Whitfield, M. G., Nolan, M. B., Ngom, J. T., Ismail, N. A., Warren, R. M., & Klopper, M. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad372 · Cited by 27
Gil, E., Sweeney, N. A., Barrett, V., Morris-Jones, S. D., Miller, R. F., Johnston, V. J., & Brown, M. (2021) · Emerging infectious diseases · doi:10.3201/eid2703.202359 · Cited by 24
“Despite this feature, bedaquiline has been used in salvage treatment for pulmonary infections with NTM (13), but little experience regarding its use for disseminated NTM infections has been published.”
BackgroundEnergetics of Respiration and Oxidative Phosphorylation in Mycobacteria
Cook, G. M., Hards, K., Vilchèze, C., Hartman, T. E., & Berney, M. (2015) · ASM Press eBooks · doi:10.1128/9781555818845.ch20 · Cited by 24
How Antibacterials Really Work: Impact on Drug Discovery
Dick, T., & Young, D. (2011) · Future Microbiology · doi:10.2217/fmb.11.26 · Cited by 21
Toward better cures for Mycobacterium abscessus lung disease
Dartois, V. A., & Dick, T. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00080-23 · Cited by 21
“Bedaquiline is bactericidal against Mtb but bacteriostatic against Mav, and while it is highly efficacious against Mtb lung infections in mice and patients and is the cornerstone of MDR-TB treatment, it is poorly efficacious in a mouse model of Mav infection (101).”
Inhibiting respiration as a novel antibiotic strategy
Lee, B. S., Singh, S., & Pethe, K. (2023) · Current Opinion in Microbiology · doi:10.1016/j.mib.2023.102327 · Cited by 16
Bown, L., Srivastava, S. K., Piercey, B. M., McIsaac, C. K., & Tahlan, K. (2017) · The Journal of Membrane Biology · doi:10.1007/s00232-017-9997-3 · Cited by 18
Treatment of pulmonary disease caused by non-tuberculous mycobacteria
van Ingen, J. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00033-8 · Cited by 15
Bedaquiline: A novel antitubercular drug for multidrug-resistant tuberculosis
Nagabushan, H., & Roopadevi, H. S. (2014) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.138772 · Cited by 19
Navigating tuberculosis drug discovery with target-based screening
Miller, C. H., & O’Toole, R. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.586999 · Cited by 10
“tuberculosis [31,32] but not Mycobacterium avium [33].”
New Insights in the Treatment of Nontuberculous Mycobacterial Pulmonary Disease
Ruth, M. M., & van Ingen, J. (2017) · Future Microbiology · doi:10.2217/fmb-2017-0144 · Cited by 7
Luo, D., Xie, W., & Wang, Z. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.02295-24 · Cited by 6
Mycobacterium avium Complex Disease
Daley, C. L. (2017) · ASM Press eBooks · doi:10.1128/9781555819866.ch40 · Cited by 7
Matar, I. K., Dong, Z., & Matta, C. F. (2024) · ChemMedChem · doi:10.1002/cmdc.202400303 · Cited by 6
Respiration and Oxidative Phosphorylation in Mycobacteria
Berney, M., & Cook, G. M. (2014) · Advances in photosynthesis and respiration · doi:10.1007/978-94-017-8742-0_15 · Cited by 4
Bédaquiline : de l’in vitro aux essais cliniques d’un nouvel antituberculeux
Guglielmetti, L., & Robert, J. (2015) · Journal des Anti-infectieux · doi:10.1016/j.antinf.2014.12.003 · Cited by 3
New therapies for nontuberculous mycobacterial lung infection
Chalmers, S. J., & Aksamit, T. R. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000815 · Cited by 1
“vivo bacteriostatic activity against MAC and MAB [53,54].”
BackgroundLamichhane, G., & Grosset, J. H. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-26273-4_7 · Cited by 1
Future Nontuberculous Mycobacteria DST and Therapeutic Interventions
Hoffner, S. E., & Ordway, D. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814692-7.00004-8
Segala, E. (2012) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 1
Aldrich, C. C., Wallis, R. S., Remmel, R. P., Hegde, P. V., & Stallings, C. L. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc298
Skerrett, S. J. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727086437.793565567
Gutiérrez, A. V. (2019) · theses.fr (ABES) · doi:10.70675/3a2fa1dbz125cz41f4z9b09zd325102dda0d
Metadata
- Authors
- Lounis, N., Gevers, T., Van Den Berg, J., Vranckx, L., & Andries, K.
- Affiliations
- Johnson & Johnson (United States) (US)
- Department of Antimicrobial Research, Tibotec BVBA, Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium
- Corresponding author
- Andries, Koen
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2009-11
- Volume
- 53
- Issue
- 11
- Pages
- 4927-4929
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2772307
- OpenAlex
- W2151030507
- Cited by
- 54
- References
- 16
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 2 · 2021: 5 · 2020: 1 · 2019: 7 · 2018: 4 · 2017: 7 · 2016: 3 · 2015: 8 · 2014: 5 · 2013: 4 · 2012: 1
- FWCI
- 0.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- ATP synthase inhibitors, bedaquiline, Mycobacterium avium, bacteriostatic activity, minimum bactericidal concentration, minimum inhibitory concentration, pharmacokinetic-pharmacodynamic relationship, nontuberculous mycobacterial infection
- MeSH terms
- Animals, Antitubercular Agents, Enzyme Inhibitors, Female, Mice, Inbred C57BL, Microbial Sensitivity Tests, Mycobacterium avium, Quinolines, Mice, Diarylquinolines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.